Nicotine replacement therapy

Smoking Cessation & Nicotine De-Addiction Product Global Market Report 2022: Increasing Approvals and Development of New Nicotine Replacement Products Creates Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, October 17, 2022
Tobacco, Retail, Pharmaceutical, Health, Online, Nicotine replacement therapy, Research report, Nicotine, Hospital, Electronic cigarette, Business Growth Fund, Use, Global, Customer support, Decision-making, Market share analysis, Value, Smoking cessation, Growth, Strategic management, Drug, CAGR, Pharmacotherapy, Drug therapy problems, Pharmacy Council of India, Nicotine gum, Tablet, Bupropion, Acquisition, Pharmacy, USD, Tobacco, Retail, Varenicline, Varenicline

This research report categorizes the Smoking Cessation & Nicotine De-Addiction Product to forecast the revenues and analyze the trends in each of the following sub-markets:

Key Points: 
  • This research report categorizes the Smoking Cessation & Nicotine De-Addiction Product to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Product, the market was studied across Drug Therapy, E-Cigarettes, Nicotine Inhalers, Nicotine Replacement Therapies, and Nicotine Sublingual Tablets.
  • The Nicotine Replacement Therapies is further studied across Nicotine Gums, Nicotine Lozenges, Nicotine Sprays, and Nicotine Transdermal Patches.
  • Based on Distribution, the market was studied across Drug Store, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.

Nicorette is Motivating Smokers to Take Healthier Breaks with a Customized Music Listening Experience, SmokeLess Break Beats

Retrieved on: 
Wednesday, July 27, 2022
Smoke, Nexium, Brain, Smoker, Occupational burnout, Nicotine, Wellness, Heart rate, Nicotine replacement therapy, Diclofenac, Student, Music therapy, Ideation, Tobacco, NYSE, Smoking, Berklee College of Music, Solution, Fatigue, Aspirin/paracetamol/caffeine, Health, Dentistry, NRT, Marketing, Relaxation, ChapStick, Centrum, TUMS, Science, Ibuprofen, Fibre supplements, Mindfulness, Program, 1-Docosanol, Nicorette, HLN, Music, Spotify, Esomeprazole, Cold medicine, Parodontax, Fluticasone propionate, Music, Sensodyne

WARREN, N.J., July 27, 2022 /PRNewswire/ -- Today, Nicorette unveils SmokeLess Break Beats – a first-of-its kind, customized music listening experience that uses the science of music therapy to address smokers' needs and motivate them towards healthier breaks. Nicorette has partnered with Berklee Music and Health Institute to enlist 30+ students and faculty to design eight original tracks, referencing scientific research about overcoming smoking addiction. These original compositions are featured in four playlists that promote relaxation, focus, confidence, and physical release, which are key benefits smokers seek in smoke breaks. Available for free on Spotify, each playlist contains the original tracks and is personalized using the listener's music history, functioning as a break-time emotional and behavioral tool to aid in smoking cessation.

Key Points: 
  • Developed in Partnership with Berklee Music and Health Institute, Program Will Feature Original Music and Encourage Smokers to Listen During Smoke-Less Breaks.
  • WARREN, N.J., July 27, 2022 /PRNewswire/ -- Today, Nicorette unveilsSmokeLess Break Beats a first-of-its kind, customized music listening experience that uses the science of music therapy to address smokers' needs and motivate them towards healthier breaks.
  • Smoke breaks are ingrained in smoking culture, serving as "treasured moments" that routinely help smokers slow down and relax.
  • SmokeLess Break Beats is designed to help smokers keep the habit of taking breaks but replace the cigarette with listening to music instead," explained Dan Wertheim, Brand Manager, U.S. Smokers' Health, Haleon.

Smoking Cessation & Nicotine De-Addiction Product Market to Reach $4.56 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 1, 2022
Health, Other Health, Online, Nicotine replacement therapy, Electronic cigarette, Drug therapy problems, USD, Nicotine, COVID-19, Bupropion, Research report, Smoking cessation, Nicotine gum, Pharmacy, CAGR, Pharmacy Council of India, Tablet, Drug, Pharmacotherapy, Hospital, Compound annual growth rate, State, Tobacco, Varenicline, Varenicline

The "Smoking Cessation & Nicotine De-Addiction Product Market Research Report by Product (Drug Therapy, E-Cigarettes, and Nicotine Inhalers), Distribution, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Smoking Cessation & Nicotine De-Addiction Product Market Research Report by Product (Drug Therapy, E-Cigarettes, and Nicotine Inhalers), Distribution, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
  • The United States Smoking Cessation & Nicotine De-Addiction Product Market size was estimated at USD 2,618.45 million in 2021 and expected to reach USD 2,882.28 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.69% to reach USD 4,562.44 million by 2027.
  • This research report categorizes the Smoking Cessation & Nicotine De-Addiction Product to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Product, the market was studied across Drug Therapy, E-Cigarettes, Nicotine Inhalers, Nicotine Replacement Therapies, and Nicotine Sublingual Tablets.
  • The Nicotine Replacement Therapies is further studied across Nicotine Gums, Nicotine Lozenges, Nicotine Sprays, and Nicotine Transdermal Patches.

Gradalis Appoints Steven Engle as Chief Executive Officer

Retrieved on: 
Thursday, June 2, 2022
Cygnus, Biology, Cell, Software, Research, GameChanger, Neoplasm, Survival, Prescient Therapeutics, BIO, Vigil, Letter, CEO, Smoking, GM, TGF, Therapy, Â, Ovarian cancer, Lupus, Biomedical engineering, Recurrence, Gene, FDA, GLOBE, Patient, Nicotine replacement therapy, University of Texas at Austin, Trial of the century, Immune system, Chairperson, Novartis, Board, Merck, University, Furin, Cancer, Pharmaceutical industry, Medical imaging, Vaccine, Pfizer, Takeda

DALLAS, June 02, 2022 (GLOBE NEWSWIRE) -- Gradalis, a late-stage stage biotechnology company developing immunotherapies for multiple cancer indications, announced today that Steven Engle has joined the company as its Chief Executive Officer.

Key Points: 
  • DALLAS, June 02, 2022 (GLOBE NEWSWIRE) -- Gradalis, a late-stage stage biotechnology company developing immunotherapies for multiple cancer indications, announced today that Steven Engle has joined the company as its Chief Executive Officer.
  • Steve joins Gradalis with over two decades of executive leadership experience with public biotech companies developing breakthrough products in the metabolic, autoimmune, oncologic and infectious disease areas.
  • Steve is a highly accomplished healthcare executive, and we are especially happy to have him leading the Gradalis team at this important time in the companys evolution, said Mr. Shanahan.
  • In addition, multiple clinical trials have demonstrated that Gradalis platform is better tolerated compared to standard cancer treatments.

Canadian Vaping Association: Academics caution that restrictive regulation has unintended consequences

Retrieved on: 
Friday, September 17, 2021
Nicotine replacement therapy, Tax, NRT, Essay, Smoker, American Public Health Association, Tobacco, Herbal cigarette, Adult, Electronic cigarette, Public health, Science, Research, Centers for Disease Control and Prevention timeline, Smoking, CVA, GLOBE

When a group of scientists join forces to advocate for vapings potential benefit to public health, governments everywhere should take notice.

Key Points: 
  • When a group of scientists join forces to advocate for vapings potential benefit to public health, governments everywhere should take notice.
  • The Canadian Vaping Association (CVA) has raised concerns surrounding Canadas current proposed flavour ban and excise tax, on the basis that such regulation would reduce the appeal of vaping and lead to increased smoking rates.
  • Vaping has proven to be an effective harm reduction tool for smokers seeking an alternative to tobacco.
  • Through vaping, Canada has seen remarkable reductions in smoking rates that had been stagnate for years.

Philip Morris International Announces Closing of Fertin Pharma Acquisition; Advances PMI’s Goal of Becoming a Majority Smoke-Free Business by 2025 and Creates Growth Opportunities Beyond Nicotine

Retrieved on: 
Wednesday, September 15, 2021
Health, Retail, Fitness & Nutrition, Tobacco, Pharmaceutical, U.S. Securities and Exchange Commission, Security (finance), Philip Morris International, Science, Food, Regulation of tobacco by the U.S. Food and Drug Administration, FDA, MRTP, Technology, Smoke, DKK, Health, Marketing, Nicotine replacement therapy, Revolution, Private Securities Litigation Reform Act, Tobacco, NYSE, Tobacco industry, Adult, CDMO, City, Solution, Tablet, Altria, Public health, Inhalation, NRT, IQOS, Contract, Sleep, Altria Group, Inc. v. Good, Nicotine, EPS, Goal, Research, Acquisition, Sale, PMI, Fine chemical, Management

The world-class expertise of Fertin aligns perfectly with this vision and will be an important part of our future.

Key Points: 
  • The world-class expertise of Fertin aligns perfectly with this vision and will be an important part of our future.
  • We are excited to join PMI and start this new chapter for Fertin Pharma, said Peter Halling, the companys Chief Executive Officer.
  • Our shared commitment to science and consumer-centric innovations forms a strong basis for a very successful future together.
  • Fertin Pharma has more than 850 employees and operations in Denmark, Canada, and India.

Canadian Vaping Association: Canada moves towards a vape flavour ban without compassion for those seeking harm reduction alternatives

Retrieved on: 
Tuesday, September 7, 2021

Though once a leader in tobacco harm reduction, Canada now considers a regressive approach to regulation, while other Commonwealth countries embrace vaping.

Key Points: 
  • Though once a leader in tobacco harm reduction, Canada now considers a regressive approach to regulation, while other Commonwealth countries embrace vaping.
  • As a harm reduction nation, Canada must ensure that smokers are receiving clear information and that an effective harm reduction tool is not invalidated by misperceptions.
  • As a harm reduction nation, Canada must support them, with care and compassion, through support of their chosen harm reduction product.
  • The Canadian Vaping Association (CVA) is a registered national, not-for-profit organization, established as the voice for the independent Canadian vaping industry.

Austria Modern Oral Tobacco Products Market report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 16, 2021
Tobacco, Retail, Psychoactive drugs, Tobacco, Smoking cessation, Electronic cigarettes, Alkaloids found in Erythroxylum coca, Anxiolytics, Nicotine, Stimulants, Pricing, Nicotine replacement therapy, Safety of electronic cigarettes

The "Market Report: Modern Oral Products in Austria" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Report: Modern Oral Products in Austria" report has been added to ResearchAndMarkets.com's offering.
  • Nicotine pouches are widely available in Austria both online and offline.
  • This report is based on our survey and analysis of both the online and offline modern oral markets.
  • It includes information on availability of modern oral products, top brands, product characteristics such as most available flavour categories and most available nicotine strengths, and pricing information.

South Korea HNB, Oral Tobacco and Nicotine Pouches Regulatory Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 16, 2021
Tobacco, Retail, Psychoactive drugs, Tobacco, Electronic cigarettes, Nicotinic agonists, Snus, Smoking cessation, Nicotine pouch, Heated tobacco product, Nicotine, Nicotine replacement therapy, Dipping tobacco

The "Regulatory Report: South Korea - HNB, Oral Tobacco and Nicotine Pouches" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Regulatory Report: South Korea - HNB, Oral Tobacco and Nicotine Pouches" report has been added to ResearchAndMarkets.com's offering.
  • All products derived from tobacco leaves are considered in South Korea as tobacco products.
  • This report outlines the regulations covering heat-not-burn products, oral tobacco, and nicotine pouches, which are regulated equally in respect of production, advertising, retail, and protection of minors.
  • These products all are subject to several taxes, but at different rates, with extremely high taxes on snus and nicotine pouches.

Finland HNB, Oral Tobacco and Nicotine Pouches Regulatory Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 9, 2021
Tobacco, Retail, Psychoactive drugs, Tobacco, Electronic cigarettes, Smoking cessation, Nicotinic agonists, Substance-related disorders, Smoking, Nicotine, Electronic cigarette, Cigarette, Regulation of electronic cigarettes, Nicotine replacement therapy

The "Regulatory Report: Finland - HNB, Oral Tobacco and Nicotine Pouches" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Regulatory Report: Finland - HNB, Oral Tobacco and Nicotine Pouches" report has been added to ResearchAndMarkets.com's offering.
  • Taxes for new products (for example, e-cigarette tax, which is 0.30/ml, regardless of nicotine content) are among the highest in the European Union.
  • Tobacco-free nicotine pouches are regulated in Finland by the Medicines Act and the Medicines Decree.
  • The Finnish Medicines Agency (Fimea) confirmed that there is only one legal medicinal nicotine pouch product on the market in Finland - Zonnic.